Summary:
The hypercoagulable state caused by the use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been cited in anecdotal reports. Since tissue factor (TF) is the main initiator of the coagulation cascade, we examined if rhG-CSF had an inductive effect on the TF-dependent pathway in 18 healthy donors receiving rhG-CSF (10 μg/kg/day × 5 days) for peripheral blood progenitor cell mobilization. After rhG-CSF, there were increases both in TF antigen (TF:Ag) (P=0.01) and TF procoagulant activity (TF:PCA) (P=0.06) plasma levels and in TF:Ag cytofluorimetric expression on CD33 (+) cells (P=0.04). Mean activities of FVIII and vWF also increased significantly. Thrombin time was slightly prolonged (P=0.06) due to significant increases in plasma D-dimer levels. In addition, while FIX activity remained stable, there were marked reductions in mean plasma FX and FII activities and a slight decrease in FVII activity that resulted in a significant prolongation of prothrombin time within normal ranges. In conclusion, the administration of rhG-CSF led to a ‘prothrombotic state’ via stimulation of TF and increased endothelial markers, such as F VIII and vWF. In the light of these findings, the use of rhG-CSF for stem cell mobilization should be undertaken cautiously in healthy donors with underlying thrombotic risk factors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anderlini P, Körbling M, Dale D et al. Allogeneic blood stem cell transplantation: consideration for donors. Blood 1997; 90: 903–908.
Anderlini P, Rizzo JD, Nugent ML et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001; 27: 689–692.
Conti JA, Scher HI . Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. Cancer 1992; 70: 2699–2702.
Barbui T, Finazzi G, Grassi A, Marchioli R . Thrombosis in cancer patients treated with hematopoietic growth factors – a meta-analysis. Thromb Haemost 1996; 75: 368–371.
Schimoda K, Okamura S, Harada N et al. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 1993; 9: 1310–1313.
Kanaji T, Okamura T, Nagafuji K et al. Megakaryocytes produce the receptor for granulocyte colony stimulating factor. Blood 1995; 85: 3359–3360, (Letter).
Kawachi Y, Watanabe A, Uchida T et al. Acute arterial thrombosis due to platelet aggregation in patient receiving granulocyte colony-stimulating factor. Br J Haematol 1996; 94: 413–416.
Rappaport SI, Rao LVM . The tissue factor pathway: how it has become a ‘Prima Ballerina’. Thromb Haemost 1995; 74: 7–17.
Nemerson Y, Giesen PLA . Some thoughts about localization and expression of tissue factor. Blood Coagul Fibrinolysis 1998; 9: 45–47.
Rao LVM, Pendurthi UR . Tissue factor on cells. Blood Coagul Fibrinolysis 1998; 9: 27–35.
Falanga A, Marchetti M, Evangelista V et al. Neutrophil activation and haemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999; 93: 2506–2514.
Kuroiwa M, Okamura T, Kanaji T et al. Effects of granulocyte colony stimulating factor on the hemostatic system in healthy volunteers. Int J Hematol 1996; 63: 311–316.
Falanga A, Marchetti M, Oldani E et al. Changes of hemostatic parameters in healthy donors administered rhG-CSF for allogeneic blood progenitor cells (PBPC) collection. Bone Marrow Transplant 1996; 17: 72a (Abstr.).
Nemerson, Y . Tissue factor in neutrophils. Thromb Haemost 2000; 83: 802.
Bussolino F, Wang JM, Paola D et al. Granulocyte- and granulocyte macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 471–472.
Blann AD, Taberner DA . A reliable marker for endothelial cell dysfunction: does it exist? Br J Haematol 1995; 90: 244–252.
LeBlanc R, Roy J, Demers C et al. Prospective study of rhG-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 1999; 23: 991–996.
Dahlback B . Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995; 73: 739–742.
Ozcan M . Changes in the natural anticoagulants following hematopoietic stem cell transplantation. Turk J Haematol 2000; 17: 138–142.
Lee KH, Lee JH, Choi SJ et al. Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 591–599.
Lindemann A, Herrmann F, Oster W et al. Hematologic effects of recombinant human granulocyte colony stimulating factor in patients with malignancy. Blood 1989; 8: 2644–2651.
Morrison AE, Green RHA, Watson D et al. Hematological and immunological changes in sibling allogeneic peripheral blood progenitor cell donors. Blood 1997; 90: 391b (Abstr.).
Østerud B . The high responder phenomenon: enhancement of LPS induced tissue factor activity in monocytes by platelets and granulocytes. Platelets 1995; 6: 119–125.
Bach RR, Moldow CF . Mechanism of tissue factor activation on HL-60 cells. Blood 1997; 89: 3270–3276.
Albrecht S, Kotzsch M, Siegert G et al. Detection of circulating tissue factor and factor VII in a normal population. Thromb Haemost 1996; 75: 772–777.
Fukuda C, Iijima K, Nakamura K . Measuring tissue factor (factor III) activity in plasma. Clin Chem 1989; 35: 1890–1897.
Hidekazu T, Nakamura S, Higure A . Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000; 127: 209–216.
sterud B, Rao LVM, Olsen JO . Induction of tissue factor expression in whole blood: lack of evidence for the presence of tissue factor expression in granulocytes. Thromb Haemost 2000; 83: 861–867.
Morton CT, Solovey A, Dandelet L . Enhanced expression of tissue factor (TF) by circulating endothelial cells following bone marrow transplantation. Blood 1998; 92: 173a (Abstr.).
Ozcan M, Morton CT, Solovey A et al. Whole blood tissue factor procoagulant activity remains during severe aplasia following bone marrow and peripheral blood stem cell transplantation. Thromb Haemost 2001; 85: 250–255.
Ozcan M, Beksac M . Is there a relationship between rhG-CSF response to conditioning regimen and engraftment after bone marrow transplantation? Bone Marrow Transplant 1998; 21: 533–535.
Kjalke M, Sorensen O, Niels B et al. Tissue factor expression by rabbit and human neutrophils. Thromb Haemost 1999; 94: 761 (Abstr.).
Acknowledgements
This study was supported by Ankara University Research Fund (99-09-00-006)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Topcuoglu, P., Arat, M., Dalva, K. et al. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant 33, 171–176 (2004). https://doi.org/10.1038/sj.bmt.1704341
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704341
Keywords
This article is cited by
-
Deep vein thrombosis: a less noticed complication in hematologic malignancies and immunologic disorders
Journal of Thrombosis and Thrombolysis (2020)
-
Granulocyte colony-stimulating factor (G-CSF) increases histone-complexed DNA plasma levels in healthy volunteers
Clinical and Experimental Medicine (2017)
-
PBSC collection from family donors in Japan: a prospective survey
Bone Marrow Transplantation (2014)
-
Drug-Induced Thrombosis: An Update
Drug Safety (2013)
-
A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients
Leukemia (2012)